Events & Presentations

Presentations

a scientist with vials being tested

Earnings Presentations

Jul 29, 2026
Q2 2026 Biogen Earnings Presentation
Apr 29, 2026
Q1 2026 Biogen Earnings Presentation
Feb 06, 2026
Q4 and Full Year 2025 Biogen Earnings Presentation
Oct 30, 2025
Q3 2025 Biogen Earnings Presentation
Jul 31, 2025
Q2 2025 Biogen Earnings Presentation
May 01, 2025
Q1 2025 Biogen Earnings Presentation
Jul 25, 2023
Q2 2023 Biogen Earnings Presentation

Conference and Other Investor Presentations

Jan 12, 2026
Biogen at the J.P. Morgan 44th Annual Healthcare Conference
Sep 03, 2025
Biogen Thematic Pipeline Seminar: Lupus Presentation
Jun 11, 2025
Biogen Thematic Pipeline Seminar: Rare Kidney Disease

Medical and Scientific Conference Presentations

Jul 14, 2026
Topline Results from CELIA: A Phase 2 Study to Evaluate the Tau-Targeting ASO Diranersen (BIIB080) in Patients with Early Alzheimer's Disease
Oct 12, 2024
Exploring higher doses of nusinersen in spinal muscular atrophy: final results from part B of the 3-part DEVOTE study
Mar 07, 2024
Interim Results From the Ongoing RESPOND Study of Nusinersen in Children With Spinal Muscular Atrophy Previously Treated With Onasemnogene Abeparvovec
Oct 25, 2023
Exploratory Clinical Outcomes From the BIIB080 Phase 1b Multiple Ascending Dose and Long-term Extension Study in Mild Alzheimer’s Disease
Jun 30, 2023
Interim Results From the Ongoing RESPOND Study
Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon

FAQs

Learn more about our Events & Presentations